Astorg-backed CordenPharma acquires peptide CDMO AmbioPharm

  • Astorg-backed CordenPharma agreed to acquire peptide API CDMO AmbioPharm to expand its global peptide development and manufacturing platform.
  • Deal adds a second US site, alongside new production and development capabilities in China via AmbioPharm’s Shanghai operations.
  • CordenPharma aims to increase US manufacturing redundancy, complementing its ongoing investment program in Colorado.
  • CordenPharma is headquartered in Switzerland, serves more than 290 customers, and runs 11 manufacturing and R&D facilities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astorg Asset Management SARL published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.